Palisade Bio, Inc.
PALI Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$1.33
KIRA · Stoqly’s AI analyst, in plain words
- Palisade Bio, Inc. had $0.0M of revenue in fiscal 2025.
- Palisade Bio, Inc. lost $16.8M in fiscal 2025.
Market cap
$281M
P/E
2.0x
Revenue
$0.0M
Net income
−$16.8M
Free cash flow
—
Operating margin
—
Palisade Bio, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$16.8M
No. It lost money last year.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
2.0x
One share costs 2.0 times its yearly profit per share.
What Palisade Bio, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 20, 2026
- Legal name
- PALISADE BIO, INC.
- CIK
- 0001357459
Palisade Bio, Inc. · PALI
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | $0.0M | $0.3M | $0.0M | $0.0M |
| Revenue growth | — | — | — | −100.0% | — |
| Operating margin | — | — | −5,228.0% | — | — |
| Net income | −$26.6M | −$14.3M | −$12.3M | −$14.4M | −$16.8M |
| Net margin | — | — | −4,920.0% | — | — |
| Diluted EPS | −$169.74 | −$16.53 | −$27.01 | −$10.19 | −$0.30 |
| Cash | |||||
| Cash from operations | −$14.8M | −$13.4M | −$11.1M | −$12.2M | −$10.8M |
| Capital expenditure | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Free cash flow | −$14.8M | −$13.4M | −$11.1M | −$12.2M | — |
| FCF margin | — | — | −4,454.8% | — | — |
| Share count change | −93.3% | 370.7% | −48.2% | 210.6% | 3,830.1% |
| Debt and strength | |||||
| Cash and short-term investments | $10.5M | $12.4M | $12.4M | $9.8M | $133M |
| Debt incl. finance leases | $0.1M | — | — | — | — |
| Shareholders' equity | $7.4M | $12.5M | $11.3M | $7.5M | $129M |
| Current ratio | 4.6x | 4.9x | 5.2x | 3.2x | 29.0x |
| Interest coverage | −17.5x | −1,209.3x | −871.3x | −1,238.3x | −1,805.6x |
| Returns and quality | |||||
| Return on equity | — | −143.7% | −103.4% | −153.6% | −24.5% |
| Return on tangible equity | −361.4% | −116.6% | −108.9% | −192.7% | −13.0% |
| Piotroski F-score | 5 | — | 5 | 1 | 3 |
| Altman Z'' | 8.4 | 24.7 | 31.3 | 38.2 | — |
Insiders bought, 12 months
$0.3M
2 insiders
Insiders sold, 12 months
$0.4M
2 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Palisade Bio, Inc. · PALI
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.33 a share, the company is worth $281M: 2.0 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001357459). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.